Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15139537 | 0.81 | CHRM1 (0.38) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL20942084 | 0.80 | MMP1 (0.35) | GRM5MMP1MMP2MMP9MMP12 | |
| SCHEMBL1712921 | 0.80 | CHRM1 (0.43) | GRM5CHRM1CHRM4CHRM5 | |
| SCHEMBL12989009 | 0.78 | CHRM1 (0.35) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12083920 | 0.78 | CHRM1 (0.41) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL1713220 | 0.76 | KCNK3 (0.39) | GRM5CHRM1CHRM2CHRM3CHRM4 | |
| SCHEMBL12293532 | 0.75 | CHRM1 (0.35) | CHRM1CHRM2CHRM3 | |
| SCHEMBL20941849 | 0.75 | MAPK1 (0.41) | MMP1MMP2MMP9MMP12CHRM1 | |
| SCHEMBL2999610 | 0.74 | RAB9A (0.44) | CHRM1 | |
| SCHEMBL3000144 | 0.74 | CHRM1 (0.39) | GRM5CHRM1CHRM2CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | claimed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | claimed |
| EP-1863490-A2 | MUSCARINIC MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | claimed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | claimed |
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| EP-1863490-A2 | MUSCARINIC MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054911-A1 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | GRM5 65/4885MMP1 4327/4885MMP2 4216/4885 |
| US-20080090826-A9 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | GRM5 65/4885MMP1 4327/4885MMP2 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.